Head-To-Head Analysis: Biocorrx (OTCMKTS:BICX) and Medpace (NASDAQ:MEDP)

Medpace (NASDAQ:MEDP) and Biocorrx (OTCMKTS:BICX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Medpace has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Institutional & Insider Ownership

78.0% of Medpace shares are held by institutional investors. 20.3% of Medpace shares are held by insiders. Comparatively, 21.4% of Biocorrx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Medpace and Biocorrx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	18.36%	91.88%	23.65%
Biocorrx	N/A	N/A	-96.39%

Analyst Ratings

This is a breakdown of current ratings for Medpace and Biocorrx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	3	9	2	0	1.93
Biocorrx	0	1	0	0	2.00

Medpace currently has a consensus price target of $491.27, suggesting a potential downside of 7.37%. Given Medpace’s higher possible upside, research analysts clearly believe Medpace is more favorable than Biocorrx.

Earnings & Valuation

This table compares Medpace and Biocorrx”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.11 billion	7.08	$404.39 million	$14.30	37.09
Biocorrx	$10,000.00	636.74	-$5.11 million	($0.32)	-0.81

Medpace has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Summary

Medpace beats Biocorrx on 11 of the 14 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.